Human rhinovirus (HRV) is the major causes of the common cold. It can cause of morbidity in patients with chronic respiratory diseases, as well as infants and the elderly. In individuals with asthma, COPD and cystic fibrosis, HRV is associated with acute exacerbations that generate high healthcare costs largely due to hospitalizations. HRV also causes bronchiolitis in infants and respiratory illness in older adults. The treatment of HRV infection is primarily supportive, including over-the-counter products aimed at symptom relief.

A broadly-protective HRV vaccine may have a significant public health impact if it could reduce or prevention of exacerbations in COPD and asthma patients. This should result in significant healthcare cost savings as hospitalization is a key direct cost during an episode. There are currently no HRV vaccines in active clinical development.

This MarketVIEW is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Rhinovirus vaccines across Western markets to 2030. Each model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon a differing pricing justifications. An up to date review is also given for latest disease background and epidemiology, along with current R&D status.

※関連の医療情報レポート

RSウイルス用ワクチンの世界市場機会分析VACZ60304 / VacZine Analytics / 2016年3月 / ...Respiratory syncytial virus (RSV) is a leading cause of acute infant/childhood (< 5yrs) lower respiratory tract infections (ALRIs) and hospitalization. In particular, elderly adults and/or those with underlying co-morbidities such as chronic obstructive pulmonary disease (COPD) or suffering with malignancies are also at increased risk of RSV infection related complications. On a global basis, RSV is estimated to be responsible for 30 million episodes and 53,000 to 199,000 deaths per year, mostly children. 99% of deaths occur in developing countries. An RSV prophylactic vaccine would ideally to reduce the incidence of severe RSV lower respiratory tract infections in “at risk”...

大腸菌（ExPEC）ワクチンの世界市場VACZ51202 / VacZine Analytics / 2015年11月 / 当調査レポートでは、大腸菌（ExPEC）ワクチンの世界市場機会について調査・分析し、ExPEC疾患の概要、疫学トレンド、リスク要因、ExPEC疾患の診断、治療戦略、研究開発動向、ワクチン接種へのアプローチ、ワクチン開発における重要要素、ターゲット製品プロファイル、商用化/市場予測モデリング・シナリオ、価格分析、大腸菌（ExPEC）ワクチンの市場規模予測結果（金額及びボリューム）などの情報をお届けいたします。...Extra intestinal pathogenic E.coli (ExPEC) is a member of the Enterobacteriaceae bacterial family. It is a leading cause of healthcare-associated (HCA) infections such as bacteraemia, urinary tract infections, neonatal sepsis and meningitis. For bacteraemias, based on a principal diagnosis from US hospital discharge data, there were an 96,560 E. coli bacteraemias in 2013 compared to 46,140 in 2000, an increase of 109%1 Although the number Streptococcal, Staphylococcal and Pneumococcal bacteraemias also increased over the same time period, in 2009, E. coli overtook Staphylococcus as the leading cause of bacteraemia. Importantly, carbapenem-resistant E. coil is also considered an “urgent” threat according...

MMRワクチン、MMRVワクチン及び水痘ワクチンの世界市場機会分析VAMV058-2014 / VacZine Analytics / 2014年10月 / 当調査レポートでは、世界のMMRワクチン（麻疹、流行性耳下腺炎、風疹）、MMRVワクチン及び水痘ワクチン市場について調査・分析し、ビジネス機会を導出しました。エグゼクティブサマリー、商用化モデル分析のOutput、世界のワクチン市場規模及び予測、地域別ワクチン市場規模及び予測、市販中のワクチン製品、市場概観、市場動向、競争状況、疫学的分析/予測、潜在市場、市場の分析モデリング、モデリング手法、分析モデリングの仮説、ターゲット製品の概要（Profile）、目標人口（顧客）、市場浸透率、市場シェア、価格設定などのデータをお届けいたします。...Measles, mumps and rubella can cause severe morbidity or even death in young children in underdeveloped countries. Because combination MMR vaccines (licensed since 1971) have led to a >99% reduction in these diseases in the US the WHO seeks to control these diseases globally. Example programs are the Measles & Rubella Initiative which has reduced global measles deaths from ~562,000 in 2000 to 122,000 in 2012 (mostly children ...

B型肝炎ワクチンの世界市場機会分析MR-VAMV033 / VacZine Analytics / 2015年3月 / 当調査レポートでは、B型肝炎ワクチンの世界市場機会について調査・分析し、B型肝炎の概要、疫学トレンド、リスク要因、B型肝炎の診断、治療戦略、研究開発動向、ワクチン接種へのアプローチ、ワクチン開発における重要要素、ターゲット製品プロファイル、商用化/市場予測モデリング・シナリオ、価格分析、B型肝炎ワクチンの市場規模予測結果（金額及びボリューム）などの情報をお届けいたします。...Hepatitis B virus (HBV) is transmitted by exposure to infectious blood or body fluids by percutaneous or mucosal means. Transmission occurs usually amongst adults exhibiting risk behaviours e.g. IDUs, MSM and heterosexuals with multiple partners although vertical transmission can occur from mother to child at birth. The HBV virus is more infectious than HIV and can cause chronic infection, resulting in cirrhosis of the liver, liver cancer, liver failure, and death. It is estimated that 2 billion people worldwide have been infected with the virus and about 600 000 people die every year due to the consequences of hepatitis B...

ロタウイルス・ワクチン（Rotavirus vaccines）：ワクチンのグローバル市場機会分析VAMV057-2014 / VacZine Analytics / 2014年6月 / ...Rotavirus transmitted by the faecal oral route causes fever and vomiting followed by diarrhoea/dehydration in neonates and infants. Recovery is usually complete but in the developing world, the virus is responsible for 5% of all deaths among children below five yrs (453,000 deaths in 2008). Improvements in water quality and sanitation do not adequately prevent the spread of rotavirus such that vaccination is the best way to prevent severe infection. In 2009, the WHO recommended that rotavirus vaccines be included in all national immunisation programs and considered a priority. Two rotavirus vaccines, Rotarix (GSK Biologicals) and Rotateq (Merck & Co)...

ヒトメタニューモウイルス（hMPV）ワクチンの世界市場機会分析MR-VAMV062 / VacZine Analytics / 2015年6月 / 当調査レポートでは、ヒトメタニューモウイルス（hMPV）ワクチンの世界市場機会について調査・分析し、ヒトメタニューモウイルス感染症の概要、疫学トレンド、リスク要因、ヒトメタニューモウイルス感染症の診断、治療戦略、研究開発動向、ワクチン接種へのアプローチ、ワクチン開発における重要要素、ターゲット製品プロファイル、商用化/市場予測モデリング・シナリオ、価格分析、ヒトメタニューモウイルスワクチンの市場規模予測結果（金額及びボリューム）などの情報をお届けいたします。...Human metapneumovirus (hMPV) is a member of the Metapneumovirus genus in the Pneumovirinae subfamily of the Paramyxoviridae family. The virus is transmitted between humans via direct or close contact and has a seasonality of infection similar to influenza and RSV. hMPV is the second most common cause of lower respiratory tract infections after RSV in young children. Most common causes for hospitalisation with hMPV are bronchiolitis and pneumonia. Mortality from hMPV occurs in 3.4–6.6% of hospitalised adults. Because of its similarity to RSV and significant global morbidity and mortality, hMPV can be considered an attractive target for a new preventative...

ノロウイルスワクチン（Norovirus vaccine）の世界市場機会分析VAMV015-2014 / VacZine Analytics / 2014年10月 / 当調査レポートでは、世界のノロウイルスワクチン市場について調査・分析し、ビジネス機会を導出しました。エグゼクティブサマリー、商用化モデル分析のOutput、世界のワクチン市場規模及び予測、地域別ワクチン市場規模及び予測、市販中のワクチン製品、市場概観、市場動向、競争状況、疫学的分析/予測、潜在市場、市場の分析モデリング、モデリング手法、分析モデリングの仮説、ターゲット製品の概要（Profile）、目標人口（顧客）、市場浸透率、市場シェア、価格設定などのデータをお届けいたします。...Noroviruses (NVs) called "Norwalk-like viruses" are a group of single-stranded positive sense RNA viruses and members of the family Caliciviridae. NVs are transmitted from human-to-human and are one of the most highly infectious viruses known. In the community, NVs most commonly cause a self-limiting mild disease of short duration with gastrointestinal symptoms usually resolving after 1 to 3 days. However, it is the sheer volume of infections and burden on healthcare systems that presents the biggest challenge. In the US, which does not yet have active national surveillance, norovirus infections may account for an estimated 1.8 million outpatient visits, 400,000...

帯状疱疹ワクチン（Herpes Zoster vaccine）の世界市場機会分析VAMV054-2014 / VacZine Analytics / 2014年10月 / 当調査レポートでは、世界の帯状疱疹ワクチン市場について調査・分析し、ビジネス機会を導出しました。エグゼクティブサマリー、商用化モデル分析のOutput、世界のワクチン市場規模及び予測、地域別ワクチン市場規模及び予測、市販中のワクチン製品、市場概観、市場動向、競争状況、疫学的分析/予測、潜在市場、市場の分析モデリング、モデリング手法、分析モデリングの仮説、ターゲット製品の概要（Profile）、目標人口（顧客）、市場浸透率、市場シェア、価格設定などのデータをお届けいたします。...Varicella-zoster virus is a ubiquitous human alphaherpesvirus, which after infection in childhood causes a relatively mild self-limiting illness. However, if the virus becomes reactivated later on in life it can cause a painful rash (shingles), often leading to postherpetic neuralgia (PHN). PHN has a significant economic burden because patients require systemic anti-viral therapy and pain management. This MarketVIEW product is a comprehensive commercial opportunity assessment detailing the potential market for Herpes Zoster vaccines (doses 000s, $ 000s) to 2030 across Western + LATAM markets. The forecast takes into account the possible introduction of new, improved Zoster vaccines from GSK Biologicals...

赤痢菌（シゲラ）用ワクチンの世界市場機会分析VACZ60302 / VacZine Analytics / 2016年1月 / ...Shigella are a highly infectious Gram-negative, non-sporulating, facultative anaerobic bacteria. They produce toxins, which cause a clinical presentation known as Shigellosis. Shigellosis comprises of systemic symptoms such as fever, headache, malaise, anorexia and occasional vomiting. Although shigellosis in otherwise healthy individuals is generally self-limiting, persistent diarrhoea in young children can be serious with the additional risk of seizures, haemolytic uraemic syndrome and other rare complications, which include encephalopathy. Most importantly, Shigella is the fifth most common known cause of diarrhoeal death in children aged ...

結核ワクチン（Tuberculosis vaccine）の世界市場機会分析VAMV021-2014 / VacZine Analytics / 2014年11月 / 当調査レポートでは、世界の結核ワクチン市場について調査・分析し、ビジネス機会を導出しました。エグゼクティブサマリー、商用化モデル分析のOutput、世界のワクチン市場規模及び予測、地域別ワクチン市場規模及び予測、市販中のワクチン製品、市場概観、市場動向、競争状況、疫学的分析/予測、潜在市場、市場の分析モデリング、モデリング手法、分析モデリングの仮説、ターゲット製品の概要（Profile）、目標人口（顧客）、市場浸透率、市場シェア、価格設定などのデータをお届けいたします。...Mycobacterium tuberculosis (M.tb) currently infects around one-third of the world's population. Although the majority of infections are latent and assymptomatic, between 5-10% of individuals develop active disease which is both contagious and able to cause severe morbidity and death. Most of M.tb infections occur in sub-saharan Africa where co-infection with HIV is a significant contributor to disease burden. The BCG vaccine has been widely adopted by greater than 100 countries with high coverage to protect against systemic TB in children. However, the vaccine does not prevent or eliminate Mtb infection, especially later in life. In many countries with high and...